<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="mn-post-cart-prior-therapies-hammond">
    <meta name="study:title" content="PF628 - Myeloid neoplasms following CAR T-cell therapy: The role of prior therapies and clonal evolution">
    <meta name="study:fileName" content="Abstracts/MN-POST-CART-PRIOR-THERAPIES-HAMMOND.html">
    <meta name="study:cancerTypes" content="B-NHL">
    <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="CAR-T cell therapy,Fludarabine,Cyclophosphamide,Chemotherapy,Lenalidomide,Alkylating agents,Hypomethylating agents">

    <title>PF628: Myeloid Neoplasms Post CAR-T (Hammond) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> </head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PF628 - Myeloid Neoplasms (MN) Post CAR T-Cell Therapy</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996 2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Background (N=39 MN Cases)</h4>
                    <p>Pts with NHL (79%) or MM (21%) post CD19/BCMA CAR-T. Est. MN incidence 2.5%. Median 5 prior LoT. Role of prior therapies & clonal evolution in MN.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>MN Characteristics & Latency</h4>
                    <p>39 MN (MDS 29, CMML 1, AML 9). Median 16mo post-CAR T. Latency from alkylating agents/autoSCT/lenalidomide ~5 yrs. Adverse cytogenetics common.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Treatment & Survival for MN</h4>
                    <p>Limited response to MN therapy (CR 7%). mOS from MN dx: 11mo. Prior lenalidomide assoc. with better mOS (14.3 vs 7.4mo, p=0.038).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Conclusion & Clonal Evolution</h4>
                    <p>MN characteristics align with therapy-related MN. Prior therapy exposure key. TP53 mutations showed clonal expansion at MN dx.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PF628 - Myeloid neoplasms following CAR T-cell therapy: The role of prior therapies and clonal evolution</h1>
            <p class="abstract-sub-header">Danielle Hammond, Koji Sasaki, Koichi Takahashi, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PF628 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Secondary myeloid neoplasms (MN) are a reported risk following chimeric antigen receptor (CAR) T-cell therapy.</li>
                        <li>Understanding the contribution of prior therapies and clonal evolution to MN development is crucial.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Study Type: Retrospective review of consecutive MN cases.</li>
                        <li>Institution: Single center.</li>
                        <li>Enrollment: Patients diagnosed with MN after receiving commercially available CAR T-cell therapy for non-myeloid hematologic malignancies since 2015.</li>
                        <li>CAR-T Products: CD19- or BCMA-targeting, with fludarabine-cyclophosphamide lymphodepletion.</li>
                        <li>Prior Therapy Assessment: Autologous stem cell transplant (autoSCT) treated as a unique line of therapy (LoT).</li>
                        <li>Clonal Evolution Analysis: Comparison of bone marrow samples within 12 months prior to CAR T and at MN diagnosis.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">Retrospective Review of Post-CAR T Myeloid Neoplasms</h3>
                        <div class="schema-enrollment">
                            <strong>MN Cases Post-CAR T (N=39)</strong>
                            <span>Primary: Non-Hodgkin B-cell Lymphoma (79%) or Multiple Myeloma (21%)</span>
                            <span>Received CD19/BCMA CAR-T (Fludarabine-Cyclophosphamide LD)</span>
                            <span>(Single Institution, Since 2015)</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group justify-around">
                            <div class="schema-phase" style="flex-basis: 100%; background-color: var(--sobi-light-gray-bg); border-color: var(--sobi-dark-blue);">
                                <strong>Data Collection & Analysis</strong>
                                <span>Patient characteristics, prior LoT (incl. autoSCT, alkylating agents, lenalidomide)</span>
                                <span>MN diagnosis details (type, cytogenetics, TP53 status)</span>
                                <span>Latency periods to MN diagnosis</span>
                                <span>MN treatment and outcomes (CR, CRi, mOS)</span>
                                <span>Clonal evolution (pre-CAR T vs MN diagnosis BM samples)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>Estimated MN Incidence</span>
                           <span>Characteristics of MN cases</span>
                           <span>Latency from CAR-T & prior therapies to MN</span>
                           <span>Survival post-MN diagnosis & prognostic factors</span>
                           <span>Evidence of clonal selection/evolution</span>
                        </div>
                    </div>
                </div>
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient & CAR-T Characteristics (Pre-MN)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Estimated MN Incidence: 2.5%.</li>
                        <li>Primary Malignancy: Non-Hodgkin B-cell lymphoma (79%), Multiple Myeloma (MM, 21%).</li>
                        <li>Median Age at CAR-T: 65 years (IQR 61-69).</li>
                        <li>Median Prior Lines of Therapy (LoT): 5 (range 1-11).</li>
                        <li>Prior autoSCT: 44% (BEAM or melphalan conditioning).</li>
                        <li>Prior Alkylating Agent Exposure: 100%.</li>
                        <li>Prior Lenalidomide Exposure: 41%.</li>
                    </ul>
                </div>
            </div> <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Results: Myeloid Neoplasm (MN) Characteristics (N=39)</h2>
                    <p class="text-sm mb-2"><strong>MN Details:</strong></p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Types: 29 MDS, 1 CMML, 9 AML.</li>
                        <li>Male: 72%.</li>
                        <li>Median Baseline BM Blasts: 6% (IQR 1-14).</li>
                        <li>Marrow Ring Sideroblasts (≥2%): 46%.</li>
                        <li>Adverse Cytogenetics: Common (Complex karyotype 44%, del(7/7q) 62%, MECOM-rearranged 13%).</li>
                        <li>Multi-hit TP53 Perturbations (ICC 2022): 46%.</li>
                    </ul>
                    <p class="text-sm font-semibold mt-3 mb-1">Latency to MN Diagnosis:</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Post CAR-T: Median 16 months (IQR 9-27); 39% within 12 months.</li>
                        <li>Post Alkylating Agents: Median 4.9 years.</li>
                        <li>Post autoSCT: Median 5.3 years.</li>
                        <li>Post Lenalidomide: Median 5.3 years.</li>
                    </ul>
                     <div class="abstract-card mt-4">
                        <h3 class="text-md font-semibold mb-2 text-center" style="color: var(--sobi-dark-blue);">Figure 1: Latency to MN Diagnosis</h3>
                        <img src="Assets/LatenciesCARTEHA241.png" alt="Figure 1: Distribution of latency periods from CAR T-cell therapy and prior treatments to MN diagnosis" class="mx-auto rounded-lg shadow-md" style="max-width: 100%; height: auto;" onerror="this.onerror=null;this.src='https://placehold.co/600x400/EBF4FA/1E3A8A?text=Figure+1+Not+Available';">
                        <p class="text-xs text-center mt-2 italic">Figure 1: Distribution of latency periods from receipt of CAR T-cell therapy to MN diagnosis (A), as well as from initial exposure to alkylating agents (B), autoSCT (C), and lenalidomide (D) to MN diagnosis.</p>
                    </div>

                    <p class="text-sm font-semibold mt-3 mb-1">MN Treatment & Outcomes:</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Supportive Care Only: 30%.</li>
                        <li>Hypomethylating Agents: 64% of treated patients.</li>
                        <li>Response to MN Therapy (n=27): CR 7% (2 pts), CRi 15% (4 pts).</li>
                        <li>AlloSCT for MN (n=6): 3 died (infection/GVHD); 3 survived with durable remission (2 TP53 WT).</li>
                        <li>Median OS from MN Diagnosis: 11.0 months (95% CI 6.1, 16.2).</li>
                        <li>Prior Lenalidomide Exposure: Improved mOS post-MN (14.3 vs 7.4 mo, p=0.038).</li>
                        <li>AlloSCT: Trend for improved mOS (14.3 vs 9.0 mo, p=0.220).</li>
                        <li>No significant mOS association with sex, age ≥65, prior autoSCT, ≥3 pre-CAR T LoT, or TP53 status.</li>
                    </ul>
                     <p class="text-sm font-semibold mt-3 mb-1">Clonal Evolution:</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Of 7 pts with TP53 sequencing pre-CAR T, 5 (71%) had TP53 mutations, all showing clonal expansion and/or second allelic hits at MN diagnosis.</li>
                    </ul>
                </div>
            </div> </div> <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>The estimated incidence of myeloid neoplasms (MN) post-CAR T-cell therapy was 2.5% in this cohort.</li>
                <li>The cytomolecular drivers (e.g., adverse cytogenetics, TP53 perturbations) and the ~5-year latency from pre-CAR T therapies (alkylating agents, autoSCT, lenalidomide) to MN diagnosis align with historical characteristics of therapy-related MN.</li>
                <li>These findings underscore the significant role of prior therapy exposures in the malignant transformation leading to MN post-CAR T.</li>
                <li>Clonal evolution of pre-existing mutations (e.g., TP53) was observed.</li>
                <li>Survival after MN diagnosis is poor, though prior lenalidomide exposure was associated with improved mOS.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>AlloSCT, Allogeneic Stem Cell Transplant; AML, Acute Myeloid Leukemia; AutoSCT, Autologous Stem Cell Transplant; BCMA, B-Cell Maturation Antigen; BEAM, Carmustine, Etoposide, Cytarabine, Melphalan; BM, Bone Marrow; CAR T, Chimeric Antigen Receptor T-cell; CD19, Cluster of Differentiation 19; CI, Confidence Interval; CMML, Chronic Myelomonocytic Leukemia; CR, Complete Remission; CRi, Complete Remission with Incomplete Hematologic Recovery; ELN, European LeukemiaNet; ICC, International Consensus Classification; IQR, Interquartile Range; LD, Lymphodepletion; LoT, Lines of Therapy; MDS, Myelodysplastic Syndromes; MECOM, MDS1 and EVI1 Complex Locus; MM, Multiple Myeloma; MN, Myeloid Neoplasms; Mo, Months; mOS, Median Overall Survival; NHL, Non-Hodgkin Lymphoma; Pts, Patients; TP53, Tumor Protein P53; WT, Wild-Type.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Hammond D, Sasaki K, Takahashi K, et al. Myeloid neoplasms following CAR T-cell therapy: The role of prior therapies and clonal evolution. Abstract #PF628 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PF628 | Abstract Release: 05/14/2025 | Presentation: 06/13/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div> <script defer src="abstract_features.js"></script>
    </body>
</html>
